ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1750

Down-Regulation of microRNA-200a-3p, Targeting C-Terminal Binding Protein-2 (CtBP2), Is Involved in Hypoproduction of IL-2 in SLE-Derived T Cells

Eri Katsuyama1, Yan Minglu1, Katsue Sunahori-Watanabe1, Sonia Zeggar1, Sumie Hiramatsu1, Keiji Ohashi1, Haruki Watanabe1, Takayuki Katsuyama1, Noriko Toyota-Tatebe2, Ken-ei Sada1 and Jun Wada1, 1Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: MicroRNA

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Animal Models - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease caused by genetic and epigenetic mechanisms. MicroRNAs (miRNAs) are small non-coding RNAs, post-transcriptionally regulate the stability of target genes via base-pairing with mRNA 3′-untranslated regions (3′-UTRs), and have been reported to be implicated in the development of autoimmune diseases. To identify candidate miRNA and its target in unbiased fashion, we conducted the RNA sequencing using CD4+ T cells from spleen of MRL/lpr (MRL) lupus model mice and C57BL/6J (B6) mice as a control. Here we newly determined candidate disease-related miRNA, miR-200a-3p, which was significantly downregulated in MRL mice. Since its target genes, CtBP and ZEB were also upregulated in MRL mice and play an important role to suppress IL-2 as a transcriptional co-suppressor complex, we examined the role of miR200-3p in increased expression of CtBP2/ZEB and subsequent defects of IL-2 production in lupus T cells.

Methods: Functional analyses were performed by transfection of miR-200a-3p mimics in EL4 mouse T cell line. The expression levels of miR-200a-3p and its target gene were examined using TaqMan Quantitative PCR (qPCR). The transcript and protein level of IL-2 under the stimulation with phorbol 12-myristate 13-acetate (PMA) (10ng/ml) and ionomycin (1uM) was examined by qPCR and ELISA respectively. Promoter activity was evaluated with luciferase plasmid containing IL-2 promoter region. Specific binding of CtBP/ZEB to IL-2 sequence that negatively regulates IL-2 expression was evaluated by electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay.

Results: We confirmed the lower expression of miR-200a-3p (p<0.0001) as well as the higher expression of CtBP2 (p<0.05) in MRL mice compared with B6 mice using qPCR. The expression level of ZEB2 was also tended to decreased (p=0.56) while ZEB1 (p<0.01) was downregulated in MRL mice by qPCR. In EL4 cells with miR-200a-3p overexpression, the expression level of ZEB and CtBP2 mRNA was significantly downregulated, while IL-2 mRNA level was upregulated by q-PCR. IL-2 concentration in the supernatant from stimulated EL4 cells was also higher under the treatment of miR-200a-3p by ELISA. IL-2 promoter activity was elevated by miR-200a-3p overexpression by luciferase assay. EMSA demonstrated that specific binding of ZEB1, ZEB2 and CtBP2 to IL-2 gene was decreased after miR-200a-3p overexpression. Finally, ChIP assay revealed that the complex of CtBP2 in regulatory sequence of IL-2 was augmented in MRL mice compared with B6 mice, while the complex was downregulated in EL4 with miR-200a-3p overexpression.

Conclusion:  Collectively, IL-2 production was elevated after miR-200a-3p overexpression by targeting ZEB1, ZEB2 and CtBP2. Our data suggest that downregulation of miR-200a-3p causes IL-2 suppression through ZEB1, ZEB2 and CtBP2 in SLE T cells, which could involve the lupus pathogenesis by dysregulation of T cells.


Disclosure: E. Katsuyama, None; Y. Minglu, None; K. Sunahori-Watanabe, None; S. Zeggar, None; S. Hiramatsu, None; K. Ohashi, None; H. Watanabe, None; T. Katsuyama, None; N. Toyota-Tatebe, None; K. E. Sada, None; J. Wada, None.

To cite this abstract in AMA style:

Katsuyama E, Minglu Y, Sunahori-Watanabe K, Zeggar S, Hiramatsu S, Ohashi K, Watanabe H, Katsuyama T, Toyota-Tatebe N, Sada KE, Wada J. Down-Regulation of microRNA-200a-3p, Targeting C-Terminal Binding Protein-2 (CtBP2), Is Involved in Hypoproduction of IL-2 in SLE-Derived T Cells [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/down-regulation-of-microrna-200a-3p-targeting-c-terminal-binding-protein-2-ctbp2-is-involved-in-hypoproduction-of-il-2-in-sle-derived-t-cells/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/down-regulation-of-microrna-200a-3p-targeting-c-terminal-binding-protein-2-ctbp2-is-involved-in-hypoproduction-of-il-2-in-sle-derived-t-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology